Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation

Elena Knops, Guido Kobbe, Rolf Kaiser, Nadine Lübke, Gabor Dunay, Annemarie Wensing, Javier Martinez-Picado, Monique Nijhuis, Johannes Fischer, Falk Hüttig, Rainer Haas, Dieter Häussinger, Björn Jensen

1 Institute of Virology, University of Cologne, Germany; 2 Department of Hematology, Oncology and Clinical Immunology, University of Düsseldorf, Germany; 3 Institute for Virology, University of Düsseldorf, Germany; 4 Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany; 5 University of Utrecht University Medical Center Utrecht Netherlands; 6 Hospital Germans Trias i Pujol A85 Research Institute iCata Sa Barcelona Spain; 7 Institute of Transplantation Diagnostics and Cell Therapeutics, University of Düsseldorf, Germany; 8 Department of Gastroenterology, Hepatology and Infectious Diseases, University of Düsseldorf, Germany

BACKGROUND
The Berlin patient is presumed to be the only person cured from HIV-infection by hematopoietic stem cell transplantation (HSCT) from a homozygous CCR5-d32 unrelated donor. Attempts to reproduce cure by HSCT have failed because of either viral rebound or death due to the underlying malignancy. We here report a 46y old patient alive, well and undetectable for HIV (RNA/DNA) three years after allogeneic CCR5-d32 HSCT.

METHODS
- Proviral DNA load: Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 assay or the Roche cobas® 6800 system (Roche Diagnostics, Germany) and 1 μL of buffy coat.
- Total DNA extraction: Roche MagNA Pure System; PBMC count (PBMC/μL): content of β-globin (LightCycler® Control Kit DNA, Roche Diagnostics, Germany) in 1 μL of buffy coat eluate. The proviral DNA load was calculated to the final result of log₉ cop/10⁹ PBMCs.
- ddPCR: in duplex mode using the QX200 platform (Bio-Rad) with primers and a probe binding a conserved region of the HIV-LTR ("Generic HIV DNA Cell", Biocentric, France) (single copy reference gene RPP30).
- Western blots (WB): New LAV Blot I (Bio-Rad).

PRE-TRANSPLANTATION
- AML diagnosis (acute myeloid leukaemia, Inv16, CBF-MYH11) in 01/2011
- Diagnosis of HIV-infection in 10/2010; initial treatment TDF/FTC+RAL;
- Complete remission (CR) of AML after 2 induction courses (ICE) + 3 consolidation courses (AML-SG07/04)
- AML relapse 09/2012; treatment: A+HAM + 2rd cycle high-dose cytarabine (HiDAC)
- 2nd CR: 8.74x10⁶/kg unmodified peripheral blood stem cells from a female 10/10 CCR5-d32 donor after conditioning with fludarabine and treosulfan in 02/2013
- HIV resistance analysis: no significant resistance mutations and the coreceptor usage was predicted as R5-tropic (Sanger sequencing: FPR 44.5%; NGS: 0.14% X4 at 3.5% FPR; geno2pheno)
- Proviral DNA load: 1.45 log₉ cop/10⁹PBMC; WB: all anticipated bands could be detected

RESULTS
- Uninterrupted continuation of ART (since 06/2014: ABC/3TC/DTG)
- VL remained undetectable in plasma and liquor
- 2nd relapse of AML in 06/2013
- Molecular remission after 8 courses of 5-Azacytidine and 4 donor lymphocyte infusions
- Proviral HIV DNA: all samples negative (<LOD: limit of detection) by conventional and ddPCR* in two different labs, namely PBMCs, rectal biopsy and bone marrow*
- Western blots: incomplete patterns with fading bands

LATEST RESULTS
- Viral Outgrowth Assay (qVOA) from PBMCs: 23 Mio CD4+ T cells - negative (IUPM<0.031/106 CD4 T cells)
- Proviral DNA in ileum biopsy: 0.1 Mio cells - 1/4 positive with LTR-, but negative with gag-primers
- HIV-LTR DNA not detected in >2 Mio PBMCs via ddPCR or qPCR, but weak positive signals in T-cell subsets (CD8 and CD4)

SUMMARY & CONCLUSION
Like in the Berlin patient, all tests from the Düsseldorf patient performed so far suggest that HIV may have been eradicated and that he may be the second individual cured from HIV by allogeneic CCR5-d32 HSCT. Further investigations, proviral DNA (ddPCR) and qVOA in lymph node, cellular immune response response assay and more, will be performed before considering the discontinuation of ART. We are grateful to the patient for his participation.